Busca avançada
Ano de início
(Referência obtida automaticamente do SciELO, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Vertical growth phase and positive sentinel node in thin melanoma

Texto completo
R.S. Oliveira Filho ; L.M. Ferreira ; L.J. Biasi ; M.M.S.S. Enokihara ; G.R. Paiva ; J. Wagner
Número total de Autores: 6
Tipo de documento: Artigo Científico
Fonte: Brazilian Journal of Medical and Biological Research; v. 36, n. 3, p. 347-350, Mar. 2003.

Sentinel node (SN) status is the most important prognostic factor for localized melanoma. Usually, patients with Breslow thickness of less than 1.0 mm are not included in SN protocols. However, the literature presents a rate ranging from 3 to 7% of nodal recurrence in thin melanoma. Ulceration, regression and high mitotic rate have been considered to be indications for an SN biopsy. The metastatic potential of the vertical growth phase is uncertain. To correlate pathological features in thin melanoma with SN metastasis, we reviewed 358 patients submitted to SN biopsy. Seventy-seven patients with lesions of 1 mm or smaller were included in the study group. Histological evaluation of the primary tumor included thickness, Clark level, mitotic rate, ulceration, regression, and growth phase. Lymphoscintigraphy was performed on all patients. Lymphatic mapping and gamma probe detection were both used for SN biopsy. Histological examination of SN consisted of hematoxylin-eosin and immunohistochemical staining. Median follow-up was 37 months. Six patients had micrometastases. Statistical analysis by the Fisher test showed that ulceration (P = 0.019), high mitotic rate (P = 0.008) and vertical growth phase (P = 0.002) were positively correlated with micrometastases. If other studies confirm these results, more melanoma patients must be submitted to SN biopsy. (AU)

Processo FAPESP: 97/02516-0 - Avaliação da linfadenectomia seletiva com biópsia de linfonodo sentinela no melanoma cutâneo estádio clínico I e II
Beneficiário:Renato Santos de Oliveira Filho
Linha de fomento: Auxílio à Pesquisa - Regular